Login to Your Account



Financings Roundup


Tuesday, February 14, 2012
• Ironwood Pharmaceuticals Inc., of Cambridge, Mass., said the underwriters of its previously announced public stock offering fully exercised their option to purchase an additional 787,500 shares at a public offering price of $15.09 per share. Including the overallotment, Ironwood sold 6.0375 million shares at $15.09 each for gross proceeds of $91.1 million and estimated net proceeds of $85.3 million. Proceeds will support launch preparations for linaclotide, which is under FDA review for irritable bowel syndrome and chronic constipation.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription